The FIGHT-207 trial, led by Jordi Rodon, associate professor of Investigational Cancer Therapeutics at MD Anderson Cancer Center, demonstrated promising early signs of clinical benefit and revealed potential mechanisms of primary and secondary resistance following treatment with the selective FGFR inhibitor pemigatinib in patients with advanced FGFR-altered solid tumors.
New research led by investigators at Massachusetts General Hospital shows that the blood pressure drug losartan can prevent immunotherapy-induced edema in patients with glioblastoma.
Scientists at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, collaborating with international researchers, have developed an AI algorithm that performs advanced computational analysis to identify potential therapeutic targets for glioblastoma multiforme and other cancers.
Cooling brain tumor cells to stop them from dividing without killing healthy cells extended the survival of glioblastoma animal models dramatically in a study led by a UT Southwestern resident.
Duke Health researchers have identified a unique process within the environment of glioblastoma brain tumors that drives resistance to immune-boosting therapies and could be targeted to promote the effects of those drugs.
A new study—published this week in Science Advances—uncovered a previously unknown genetic process that could inform the development of novel treatment options for glioblastoma.
A new class of small molecule drugs, now in phase I clinical trials, is the first to target circadian clock proteins, which play a key role in the recurrence and spread of glioblastoma.
A gene that UVA Health researchers discovered is responsible for the deadliest type of brain tumor is also responsible for two forms of childhood cancer, the scientists have found.
A study led by investigators at the University of Alabama at Birmingham and Nationwide Children’s Hospital has provided additional evidence of the efficacy of virotherapy for glioblastoma.
Oncoceutics Inc. announced results from the first cohort of its phase II trial for patients with recurrent glioblastoma, which showed median overall survival in the first cohort of 17 patients two times that indicated in the current GBM patient literature.
